论文部分内容阅读
Teicoplanin是一种新的万古霉素-利托菌素族的糖肽类抗生素,有抗革蓝氏阳性需氧和厌氧细菌的活性。肾功能正常的病人,可每日静脉注射给药,主要从尿液中排泄。本文报道研究肾功能受损病人和正常志愿者的Teicoplanin药代动力学,并据此确定对肾功能受损病人给药的剂量基准。研究是在20位肾功能有不同程度受损的成年病人里进行的,平均体重为70±14kg,他们的肾功能以肌酐酸清除率(Clcr)测出值表示,介于2至150毫升·分~(-1)之间。每位静脉注射Teicoplanin 200毫克,过5分钟后采集基准的血和尿样品。在给药后第0.5、1、2、4、
Teicoplanin is a new vancomycin-Rituxan glycopeptide antibiotic with activity against Gram-positive aerobic and anaerobic bacteria. Patients with normal renal function, daily intravenous administration, mainly from the urine. This article reports the pharmacokinetics of Teicoplanin in patients with impaired renal function and in normal volunteers, and based on this, determines the dose basis for patients with impaired renal function. The study was performed on 20 adult patients with varying degrees of renal function impairment with an average body weight of 70 ± 14 kg and their renal function was measured as creatinine clearance (Clcr) values ranging from 2 to 150 ml · Points ~ (-1) between. Each intravenous Teicoplanin 200 mg, after 5 minutes to collect baseline blood and urine samples. At 0.5, 1, 2, 4,